2023
Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.
Kurz S, Zan E, Cordova C, Troxel A, Barbaro M, Silverman J, Snuderl M, Zagzag D, Kondziolka D, Golfinos J, Chi A, Sulman E. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clinical Cancer Research 2023, 30: 680-686. PMID: 38048045, DOI: 10.1158/1078-0432.ccr-23-2533.Peer-Reviewed Original ResearchConceptsProgression-free survivalSomatostatin receptor type 2PFS-6Stable diseaseOverall survivalIntracranial meningiomasSingle-arm phase II clinical studyMedian progression-free survivalPhase II clinical studyImaging biomarkersCourse of radiationReceptor type 2Multicenter clinical trialMacdonald criteriaMedian OSRadiographic responseProgressive meningiomasTumor measurementsTumor resectionMedian agePrimary endpointRadiotherapeutic interventionSecondary endpointsMedical therapyAdult patients
2020
Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas
Cordova C, Kurz S. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas. Current Oncology Reports 2020, 22: 84. PMID: 32617743, DOI: 10.1007/s11912-020-00937-4.Peer-Reviewed Original ResearchConceptsWHO classification of CNS tumorsClassification of CNS tumorsWHO classificationCNS tumorsWHO grade IDNA methylation patternsBiology of meningiomasClinical trial designPrognostic implicationsTERT promoterTumor biologyGrade IMethylation patternsHistopathological featuresGenetic alterationsEffective therapyLoss of functionMeningiomasMolecular classificationReviewOur understandingDMD geneEpigenetic alterationsTumorEpigenetic changesTherapeutic opportunities